PAD2 has been reported to be highly expressed in tumor tissues and the blood of patients with one of several cancers, especially breast, liver, gastric and cervical carcinomas [81,82], and when overexpressed, PAD2 may suppress androgen activity in malignant tissues of castration-resistant prostate cancer (CRPC) patients [83]. This evidence concerns the gene PADI2 and cervical carcinoma.